Literature DB >> 20870313

Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.

Andrei I Khlebnikov1, Igor A Schepetkin, Mark T Quinn.   

Abstract

N-formyl peptide receptors (FPRs) are important in host defense. Because of the potential for FPRs as therapeutic targets, recent efforts have focused on identification of non-peptide agonists for two FPR subtypes, FPR1 and FPR2. Given that a number of specific small-molecule agonists have recently been identified, we hypothesized that computational structure-activity relationship (SAR) analysis of these molecules could provide new information regarding molecular features required for activity. We used a training set of 71 compounds, including 10 FPR1-specific agonists, 36 FPR2-specific agonists, and 25 non-active analogs. A sequence of (1) one-way analysis of variance selection, (2) cluster analysis, (3) linear discriminant analysis, and (4) classification tree analysis led to the derivation of SAR rules with high (95.8%) accuracy for correct classification of compounds. These SAR rules revealed key features distinguishing FPR1 versus FPR2 agonists. To verify predictive ability, we evaluated a test set of 17 additional FPR agonists, and found that the majority of these agonists (>94%) were classified correctly as agonists. This study represents the first successful application of classification tree methodology based on atom pairs to SAR analysis of FPR agonists. Importantly, these SAR rules represent a relatively simple classification approach for virtual screening of FPR1/FPR2 agonists.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870313      PMCID: PMC2953788          DOI: 10.1016/j.ejmech.2010.09.001

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  28 in total

Review 1.  Structure-activity relationship approaches and applications.

Authors:  Weida Tong; William J Welsh; Leming Shi; Hong Fang; Roger Perkins
Journal:  Environ Toxicol Chem       Date:  2003-08       Impact factor: 3.742

2.  Structure-activity relationship study of oxindole-based inhibitors of cyclin-dependent kinases based on least-squares support vector machines.

Authors:  Jiazhong Li; Huanxiang Liu; Xiaojun Yao; Mancang Liu; Zhide Hu; Botao Fan
Journal:  Anal Chim Acta       Date:  2006-08-24       Impact factor: 6.558

3.  Target specific compound identification using a support vector machine.

Authors:  Dariusz Plewczynski; Marcin von Grotthuss; Stephane A H Spieser; Leszek Rychlewski; Lucjan S Wyrwicz; Krzysztof Ginalski; Uwe Koch
Journal:  Comb Chem High Throughput Screen       Date:  2007-03       Impact factor: 1.339

Review 4.  Applications of 2D descriptors in drug design: a DRAGON tale.

Authors:  Aliuska Morales Helguera; Robert D Combes; Maykel Pérez González; M Natália D S Cordeiro
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

5.  Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents.

Authors:  Roland W Bürli; Han Xu; Xiaoming Zou; Kristine Muller; Jennifer Golden; Mike Frohn; Matthew Adlam; Matthew H Plant; Min Wong; Michele McElvain; Kelly Regal; Vellarkad N Viswanadhan; Philip Tagari; Randall Hungate
Journal:  Bioorg Med Chem Lett       Date:  2006-05-11       Impact factor: 2.823

6.  Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Jun Tian; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

7.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

Review 8.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

9.  6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.

Authors:  Agostino Cilibrizzi; Mark T Quinn; Liliya N Kirpotina; Igor A Schepetkin; Jeff Holderness; Richard D Ye; Marie-Josephe Rabiet; Claudio Biancalani; Nicoletta Cesari; Alessia Graziano; Claudia Vergelli; Stefano Pieretti; Vittorio Dal Piaz; Maria Paola Giovannoni
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  A novel nonpeptide ligand for formyl peptide receptor-like 1.

Authors:  Masakatsu Nanamori; Xiyuan Cheng; Jianghua Mei; Hairong Sang; Yunxia Xuan; Caihong Zhou; Ming-Wei Wang; Richard D Ye
Journal:  Mol Pharmacol       Date:  2004-08-12       Impact factor: 4.436

View more
  4 in total

1.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

Review 2.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

3.  Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity.

Authors:  Niccolo Cantini; Igor A Schepetkin; Nadezhda V Danilenko; Andrei I Khlebnikov; Letizia Crocetti; Maria Paola Giovannoni; Liliya N Kirpotina; Mark T Quinn
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

Review 4.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.